Recombinant SARS-CoV-2 Spike S1 Subunit Fc Protein, CF

Name: Recombinant SARS-CoV-2 Spike S1 Subunit Fc Protein, CF
Brand: R&D Systems
SKU: 10623-CV

Catalog # 10623-CV

Citations (1)

Product Datasheet / COA / SDS

CHO Expressed

Order Information

Bio-Techne Corporation

tel: (800) 343-7475 (free phone)

tel: (612) 379-2956

customercare.na@bio-techne.com

100% Guarantee on all
R&D Systems products.

Shipping Information

$35 to United States

Products in stock will be shipped in 1-3 business days unless specified.

View Distributors

Key Product Details

Source:	CHO
Accession #:	YP_009724390.1
Structure / Form:	Disulfide-linked homodimer
Applications:	Bioactivity

View Full Technical Details for Recombinant SARS-CoV-2 Spike S1 Subunit Fc Protein, CF

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived sars-cov-2 Spike S1 Subunit protein

SARS-CoV-2 Spike S1 Subunit (Val16-Pro681) Accession # YP_009724390.1	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal sequence Analysis

Val16

Predicted Molecular Mass

101 kDa

SDS-PAGE

120-150 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag (Catalog # 933-ZN).

Recombinant SARS-CoV-2 Spike S1 Subunit Fc Protein, CF Scientific Data Examples

	Recombinant SARS-CoV-2 Spike S1 Subunit Fc Chimera Protein Binding Activity. Recombinant SARS-CoV-2 Spike S1 Subunit Fc Chimera (Catalog # 10622-CV) binds Recombinant Human ACE-2 His-tag (933-ZN) in a functional ELISA.
	Recombinant SARS-CoV-2 Spike S1 Subunit Fc Chimera Protein SDS-PAGE. 2 μg/lane of Recombinant SARS-CoV-2 Spike S1 Subunit Fc Chimera Protein (Catalog # 10623-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 120-150 kDa and 230-280 kDa, respectively.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10623-CV

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: Spike S1 Subunit

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein(S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a homotrimeric glycoprotein that mediates membrane fusion and viral entry. As with most coronaviruses, proteolytic cleavage of the SARS-CoV-2 S protein into two distinct peptides, S1 and S2 subunits, is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). Based on structural biology studies, the receptor binding domain (RBD), located in the C-terminal region of S1, can be oriented either in the up/standing or down/lying state (6). The standing state is associated with higher pathogenicity and both SARS-CoV-1 and MERS can access this state due to the flexibility in their respective RBDs. A similar two-state structure and flexibility is found in the SARS-CoV-2 RBD (7). Based on amino acid (aa) sequence homology, the SARS-CoV-2 S1 subunit has 65% identity with SARS-CoV-1 S1 subunit, but only 22% homology with the MERS S1 subunit. The low aa sequence homology is consistent with the finding that SARS and MERS bind different cellular receptors (8). The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds Angiotensin-Converting Enzyme 2 (ACE-2), but with much higher affinity and faster binding kinetics (9). Before binding to the ACE-2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains in the trimeric structure is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy (10). Polyclonal antibodies to the RBD of the SARS-CoV-2 S1 subunit have been shown to inhibit interaction with the ACE-2 receptor, confirming S1 subunit especially RBD as an attractive target for vaccinations or antiviral therapy (11). There is also promising work showing that the RBD may be used to detect presence of neutralizing antibodies present in a patient's bloodstream, consistent with developed immunity after exposure to the SARS-CoV-2 virus (12). Lastly, it has been demonstrated the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (13, 14).

Item	Value
References	Wu, F. et al. (2020) Nature 579:265. Tortorici, M.A. and D. Veesler (2019). Adv. Virus Res. 105:93. Bosch, B.J. et al. (2003). J. Virol. 77:8801. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871. Millet, J.K. and G. R. Whittaker (2015) Virus Res. 202:120. Yuan, Y. et al. (2017) Nat. Commun. 8:15092. Walls, A.C. et al. (2010) Cell 180:281. Jiang, S. et al. (2020) Trends. Immunol. https://doi.org/10.1016/j.it.2020.03.007. Ortega, J.T. et al. (2020) EXCLI J. 19:410. Wrapp, D. et al. (2020) Science 367:1260. Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007. Okba, N. M. A. et al. (2020). Emerg. Infect. Dis. https://doi.org/10.3201/eid2607.200841. Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9. Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.
Long Name	Spike Protein, S1 Subunit
Alternate Names	SARS-CoV-2, Spike S1 Subunit

Citations for Recombinant SARS-CoV-2 Spike S1 Subunit Fc Protein, CF (1)

Showing 1 - 1 of 1 citation Showing All

View all citations for the Proteins and Enzymes platform.

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant SARS-CoV-2 Spike S1 Subunit Fc Protein, CF include:

Species: Human
Sample Types: Whole Cells
Applications: Bioassay

W Ouyang et al. (2021), Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo International Journal of Molecular Sciences, 22(14).
PMID: 34299155

There are no citations that match your criteria.

Showing 1 - 1 of 1 citation Showing All

Product Documents

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS